Based on our study, we conclude that, (a) MCL subtypes with specific mutations in TP53 and ATM affect the way that the serum proteome changes upon treatment, emphasizing that the response is dependent on specific features of the tumor biology. This evidence concerns the gene ATM and neoplasm.